Real-world Observational Study of Targeted Therapy in Patients With Advanced ROS1-positive NSCLC

Not yet recruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

December 1, 2026

Study Completion Date

December 1, 2027

Conditions

Non-Small Cell Lung CancerROS1 Gene RearrangementResistanceTargeted Therapy

Interventions

DRUG

Entrectinib

Patients in each cohort were treated with Entrectinib.

All Listed Sponsors

lead

National Cancer Center, China

OTHER

NCT06694129 - Real-world Observational Study of Targeted Therapy in Patients With Advanced ROS1-positive NSCLC | Biotech Hunter | Biotech Hunter